BIVI Stock Summary and Trading Ideas (Biovie | NASDAQ:BIVI)

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Biovie trades on the NASDAQ stock market under the symbol BIVI.

As of April 14, 2026, BIVI stock price climbed to $1.46 with 32,670 million shares trading.

BIVI has a beta of -0.25, meaning it tends to be less sensitive to market movements. BIVI has a correlation of 0.00 to the broad based SPY ETF.

BIVI has a market cap of $11.00 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BIVI traded as high as $869.00 and as low as $1.06.

The top ETF exchange traded funds that BIVI belongs to (by Net Assets): VTI, VXF.

BIVI has underperformed the market in the last year with a price return of -83.1% while the SPY ETF gained +30.2%. However, in the short term, BIVI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.7% vs +0.9% return in SPY. But in the last 2 weeks, BIVI shares have been beat by the market, returning +4.3% compared to an SPY return of +6.8%.

BIVI support price is $1.31 and resistance is $1.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIVI shares will trade within this expected range on the day.